6 ms·
And no one was willing to pay this much for the drug, but the inexplicably decided no revenue was better than lowering the price.
by ineedasername 8y ago
And no one was willing to pay this much for the drug, but the inexplicably decided no revenue was better than lowering the price.
- flatline 8y agoHow much does it cost to manufacture the drug, and in such relatively low quantities? The article did not say but it pointed to this as part of their decision.
- tptacek 8y agoIt's not "inexplicable". uniQure is a going concern with treatments in the pipeline for Huntingtons, hemophilia, and congestive heart failure. They have a finite amount of resources and are allocating them to projects that they're more optimistic about than this one. Glybera is of questionable efficacy and is very expensive to administer (they're on the hook for long-term monitoring for everyone they dose). It's not at all hard to see why they'd stop production.
- obmelvin 8y agoYeah, but the drug also has weak efficacy. Who cares if it is "only" 100k instead of 1M if it do what it claims?
- NickM 8y agoMaybe caving in and lowering the revenue would encourage future customers for other expensive treatments to boycott high prices and hold off for price drops. Refusing to negotiate and forgoing revenue now could be the rational strategy in the long term.
- ctdonath 8y ago"Pay" goes both ways. The manufacturer wasn't willing to pay for a million dollars by making this treatment.